These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 16707392)

  • 21. Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Tramper-Stranders GA; Wolfs TF; van Haren Noman S; van Aalderen WM; Nagelkerke AF; Nuijsink M; Kimpen JL; van der Ent CK
    Thorax; 2010 Oct; 65(10):915-20. PubMed ID: 20729233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors associated with mucoid transition of Pseudomonas aeruginosa in cystic fibrosis patients.
    Martha B; Croisier D; Fanton A; Astruc K; Piroth L; Huet F; Chavanet P
    Clin Microbiol Infect; 2010 Jun; 16(6):617-23. PubMed ID: 20002106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.
    Taccetti G; Campana S; Festini F; Mascherini M; Döring G
    Eur Respir J; 2005 Sep; 26(3):458-61. PubMed ID: 16135728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pseudomonas aeruginosa and cystic fibrosis: first colonization to chronic infection].
    Laurans M; Arion A; Fines-Guyon M; Regeasse A; Brouard J; Leclercq R; Duhamel JF
    Arch Pediatr; 2006 Oct; 13 Suppl 1():S22-9. PubMed ID: 17370393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center.
    Lee TW; Brownlee KG; Denton M; Littlewood JM; Conway SP
    Pediatr Pulmonol; 2004 Feb; 37(2):104-10. PubMed ID: 14730654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secretory IgA response against Pseudomonas aeruginosa in the upper airways and the link with chronic lung infection in cystic fibrosis.
    Mauch RM; Rossi CL; Aiello TB; Ribeiro JD; Ribeiro AF; Høiby N; Levy CE
    Pathog Dis; 2017 Aug; 75(6):. PubMed ID: 28645157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pseudomonas aeruginosa diversity in distinct paediatric patient groups.
    Tramper-Stranders GA; van der Ent CK; Wolfs TF; Kimpen JL; Fleer A; Johansen U; Johansen HK; Høiby N
    Clin Microbiol Infect; 2008 Oct; 14(10):935-41. PubMed ID: 18752596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Association between chronic colonization or infection with Pseudomonas aeruginosa and bronchial hyperreactivity in patients with cystic fibrosis].
    Valverde-Molina J; Sánchez-Solís M; Pastor-Vivero MD; García-Marcos L
    Arch Bronconeumol; 2008 Apr; 44(4):180-4. PubMed ID: 18423178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study.
    Kollberg H; Carlander D; Olesen H; Wejåker PE; Johannesson M; Larsson A
    Pediatr Pulmonol; 2003 Jun; 35(6):433-40. PubMed ID: 12746939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pseudomonas aeruginosa in the home environment of newly infected cystic fibrosis patients.
    Schelstraete P; Van Daele S; De Boeck K; Proesmans M; Lebecque P; Leclercq-Foucart J; Malfroot A; Vaneechoutte M; De Baets F
    Eur Respir J; 2008 Apr; 31(4):822-9. PubMed ID: 18094014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Value of serology in predicting Pseudomonas aeruginosa infection in young children with cystic fibrosis.
    Douglas TA; Brennan S; Berry L; Winfield K; Wainwright CE; Grimwood K; Stick SM; Sly PD;
    Thorax; 2010 Nov; 65(11):985-90. PubMed ID: 20889526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort.
    Rosenfeld M; Emerson J; McNamara S; Joubran K; Retsch-Bogart G; Graff GR; Gutierrez HH; Kanga JF; Lahiri T; Noyes B; Ramsey B; Ren CL; Schechter M; Morgan W; Gibson RL;
    Pediatr Pulmonol; 2010 Sep; 45(9):934-44. PubMed ID: 20597081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.
    Emerson J; Rosenfeld M; McNamara S; Ramsey B; Gibson RL
    Pediatr Pulmonol; 2002 Aug; 34(2):91-100. PubMed ID: 12112774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis.
    Griese M; Müller I; Reinhardt D
    Eur J Med Res; 2002 Feb; 7(2):79-80. PubMed ID: 11891148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How and why to monitor Pseudomonas aeruginosa infections in the long term at a cystic fibrosis centre.
    Kalferstova L; Vilimovska Dedeckova K; Antuskova M; Melter O; Drevinek P
    J Hosp Infect; 2016 Jan; 92(1):54-60. PubMed ID: 26597636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Flagellin induces myeloid-derived suppressor cells: implications for Pseudomonas aeruginosa infection in cystic fibrosis lung disease.
    Rieber N; Brand A; Hector A; Graepler-Mainka U; Ost M; Schäfer I; Wecker I; Neri D; Wirth A; Mays L; Zundel S; Fuchs J; Handgretinger R; Stern M; Hogardt M; Döring G; Riethmüller J; Kormann M; Hartl D
    J Immunol; 2013 Feb; 190(3):1276-84. PubMed ID: 23277486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Greally P; Whitaker P; Peckham D
    Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relative increase in IgG antibodies to Pseudomonas aeruginosa 60-kDa GroEL in prediabetic patients with cystic fibrosis.
    Jensen P; Johansen HK; Lanng S; Høiby N
    Pediatr Res; 2001 Mar; 49(3):423-8. PubMed ID: 11228271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cystic fibrosis transmembrane conductance regulator (CFTR)-mediated residual chloride secretion does not protect against early chronic Pseudomonas aeruginosa infection in F508del homozygous cystic fibrosis patients.
    Derichs N; Mekus F; Bronsveld I; Bijman J; Veeze HJ; von der Hardt H; Tummler B; Ballmann M
    Pediatr Res; 2004 Jan; 55(1):69-75. PubMed ID: 14605249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and laboratory correlations in patients with cystic fibrosis and Pseudomonas aeruginosa infection: The experience of a regional centre.
    Smădeanu R; Moşescu S; Zăpucioiu C; Orăşeanu D
    Pneumologia; 2016; 65(4):201-6. PubMed ID: 29542902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.